Analysts Lift Average Price Targets for Kazia Therapeutics and VTEX
Average Kazia target rises to $31.83 and VTEX to $5.46, with VTEX consensus shifting to Hold. Data from TradingView, based on FactSet.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to six analysts, the average 12-month price target for Kazia Therapeutics moved from $31.57 to $31.83, with forecasts spanning $25 to $40. Measured against the October 23 close, the updated target points to roughly 308% potential upside. The consensus stays at Buy, with six Buy ratings and no Holds or Sells.
For VTEX, eight analysts raised the average target from $5.41 to $5.46, with estimates between $4 and $12. That implies about 31% potential upside, but the consensus has shifted to Hold, with two Buy ratings, six Holds and no Sells.
why it matters
Revisions like these are routine analyst activity, and small changes in average targets rarely move the broader market. The shift in VTEX consensus toward Hold suggests some analysts have become more cautious about the stock. The figures come from TradingView, citing FactSet, and do not constitute investment advice.
tags
instruments
sources
- Kazia Therapeutics Limited Stock 12‑Month Price Target Raised to $31.83, Implies 308% Upside — TradingView, 24 October 2026 at 22:20 UTC
- VTEX Stock 12‑Month Price Target Raised to $5.46, Implies 31% Upside — TradingView, 24 October 2026 at 22:20 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗